Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor

US11654143B2 · kind B2 · utility

Assignee

• Acerta Pharma B.V. · NL

Inventors

• Ahmed Hamdy · Santa Cruz, US
• Wayne Rothbaum · New York, US
• Raquel Izumi · Redwood City, US
• Brian Lannutti · Solana Beach, US
• Todd Covey · Redwood City, US
• Roger Ulrich · Köniz, CH
• David M. Johnson · Rio Del Mar, US
• Tjeerd Barf · Ravenstein, NL
• Allard Kaptein · Zaltbommel, NL

Key dates

• Filing date: Jul 8, 2021
• Grant date: May 23, 2023
• Expiry date: Sep 25, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.